Dabrafenib, 50 mg

STEMCELL Technologies offers Dabrafenib, a reversible, selective, and ATP-competitive inhibitor of B-RAF. It shows higher potency towards V600E mutant B-RAF over wild-type B-RAF or C-RAF, with IC₅₀ values of 0.8, 3.2, and 5 nM, respectively (Laquerre et al.; Menzies et al.). The compound is also known by alternative names including GSK 2118436, Dabarefenib, and Tafinlar™ (CAS Number 1195765-45-7).

Published applications include cancer research, where the compound decreases ERK phosphorylation and inhibits cell proliferation in cells expressing the B-RAF V600E mutation, and prevents tumor growth in mouse xenograft models of B-RAF(V600E) human melanoma and colon cancer (Rheault et al.). It also has applications in disease modeling, where it alleviates acetaminophen-induced liver injury through distinct nanomolar inhibition of receptor-interacting protein (RIP3) in mice (Li et al.).

For storage, the product is stable at –20°C as supplied and should be protected from prolonged exposure to light. Reported solubility indicates DMSO ≤ 55 mM and absolute ethanol ≤ 2 mM. To prepare a 10 mM stock solution in DMSO, resuspend 10 mg in 1.92 mL of DMSO. The source recommends preparing stock solution fresh before use and storing in DMSO at –20°C, aliquoting into working volumes to avoid repeated freeze-thaw cycles. The compound has low solubility in aqueous media; for use as a cell culture supplement, stock solution should be diluted into culture medium immediately before use, avoiding final DMSO concentration above 0.1% due to potential cell toxicity.